首页> 外文期刊>Vojnosanitetski Pregled >Efficacy of Botulinum toxin type A in treatment of different forms of focal dystonias in the Serbian population: Experience of the Botulinum Toxin Outpatients Department
【24h】

Efficacy of Botulinum toxin type A in treatment of different forms of focal dystonias in the Serbian population: Experience of the Botulinum Toxin Outpatients Department

机译:A型肉毒毒素治疗塞尔维亚人群不同形式的局灶性肌张力障碍的功效:肉毒毒素门诊部的经验

获取原文
           

摘要

Background/Aim. Botulinum toxin (BTX) irreversibly inhibits presynaptic acetylcholine release with subsequent relaxation of abnormally contracting muscles. It is an effective and well tolerated treatment with long-term benefit in a variety of movement disorders and other neurological and non-neurological disturbances. The aim of our study was to present our experience with BTX type A in treatment of different forms of focal dystonias. Мethods. А hundred of patients with different focal dystonias (spastic torticollis, blepharospasm and graphospasm) from the Botulinum Toxin Outpatients Department, Clinic for Neurology, Clinical Center of Serbia, were included in the study. All the patients were examined and rated at baseline visit prior to BTX application and on the following visit, after 3-4 months, using self-assessment improvement questionnaire and standardized rating scales. Results. The improvement of ≥ 50% was presented in 68.2% of all (199) the analyzed applications. Independent predictors of good response to the therapy (improvement ≥ 50%) were male sex (p = 0.011), the presence of sensory trick (p = 0.013) and the total number of BTX applications (p = 0.002). The patients with spastic torticollis and blepharospasm showed a statistically significantly better BTX effect (improvement 57.3 ± 27.5% and 54.1 ± 28.3%), respectively than the graphospasm group (26.7 ± 25.6%). Most of the patients did not have therapy complications (81.4% and 72% in two applications). Side effects in the remaining patients (muscle weakness, dysphagia, ptosis, double vision, neck weakness and lacrimal dysfunction) lasted for 28.3 ± 18.6 days after the first treatment and 32.5 ± 36.2 days after the second one. Conclusion. BTX is safe and highly effective in long-term treatment of patients with different forms of focal dystonia, with only mild and well-tolerated side-effects. [Projekat Ministarstva nauke Republike Srbije, br. 175090]
机译:背景/目标。肉毒杆菌毒素(BTX)不可逆地抑制突触前乙酰胆碱的释放,并随后放松异常收缩的肌肉。它是一种有效且耐受性良好的治疗方法,可对多种运动障碍以及其他神经系统和非神经系统疾病产生长期的益处。我们研究的目的是介绍我们使用BTX A型治疗不同形式的局灶性肌张力障碍的经验。 Мethods。塞尔维亚临床中心神经病学门诊肉毒杆菌毒素门诊部的数百名患有不同局灶性肌张力障碍(痉挛性斜颈,眼睑痉挛和痉挛性痉挛)的患者被纳入研究。所有患者均在接受BTX之前的基线访视时进行检查并进行评分,并在3-4个月后的下次访视中使用自我评估改善问卷和标准化评分表进行评估。结果。在所有分析的应用程序(199个)中,有68.2%提出了≥50%的改进。对治疗有良好反应(改善≥50%)的独立预测因素是男性(p = 0.011),感觉技巧的存在(p = 0.013)和BTX应用的总数(p = 0.002)。痉挛性斜颈和眼睑痉挛的患者显示BTX效果在统计学上显着优于石墨痉挛组(26.7±25.6%)(改善57.3±27.5%和54.1±28.3%)。大多数患者没有治疗并发症(两次应用中分别占81.4%和72%)。其余患者的副作用(肌肉无力,吞咽困难,上睑下垂,复视,颈部无力和泪道功能障碍)在第一次治疗后持续28.3±18.6天,在第二次治疗后持续32.5±36.2天。结论。 BTX在长期治疗具有不同形式的局灶性肌张力障碍的患者中是安全且高效的,仅具有轻度和良好耐受的副作用。 [Projekat Ministarstva nauke Republike Srbije,br。 175090]

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号